Predictive value of fibrinolytic factors in coronary heart disease

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 59, Issue 230, 1999, Pages 23-31

  Wiman, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; COMPLEMENT COMPONENT C1S INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBRINOLYSIS; HEART INFARCTION; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOEMBOLISM; BLOOD; CORONARY ARTERY DISEASE; PREDICTION AND FORECASTING; REVIEW;

ANGINA;

BIOLOGICAL MARKERS; CORONARY DISEASE; FIBRINOLYSIS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032615858     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519909168323     Document Type: Conference Paper

References (50)

1. Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Current opinion in Hematology 1996;3:372-378.
2. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma:risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
3. Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients - a case-control study. Arterioscler Thromb 1993;13:1412-1417.
4. Held C, Hjelmdahl P, Rehnqvist N, Wallen H, Björkander I, Eriksson S, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997;95:2380-2386.
5. Jansson JH, Nilsson TK, Olofsson BO:Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-161.
6. Ridker PM, Vaughan PE, Stampfer MJ. Manson JE, Hennehens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
7. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996;75:607-611.
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;322:635-641.
9. Nilsson TK. Analysis of factors affecting tissue plasminogen activity and antigen concentration before and after venous occlusion in 123 patients. Clin Chem Enzymol Comm 1989;1:335-341.
10. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991;34:179-192.
11. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma:correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 1998;58:475-484.
12. Wiman, B, and Collen, D. On the Molecular Mechanisms of Physiological Fibrinolysis. Nature 1978;272:549-550.
13. Chmielewska J, Rånby M, Wiman B:Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-436.
14. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F:Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907-913.
15. Chmielewska J, Rånby M, Wiman B:Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. Biochem J 1988;251:327-332.
16. Wiman B, Haegerstrand-Björkman M:Plasmin/ 2-antiplasmin complex in plasma - a global fibrinolytic assay. Thromb Haemostas 1993;69:1091, abstract no 1958.
17. Pedersen OD, Gram J, Jespersen J:Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemostas 1995;73:835-840.
18. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D:Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A 1983;80:2956-2960.
19. Gelehrter TD, Barouski Miller PA, Coleman PL, Cwikel BJ:Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983;53-54:11-21.
20. Laug W:Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. Thromb Haemostat 1985;53:165-169.
21. Kruithof EKO, Tran-Thang C, Bachman F:Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostat 1986;55:201-205.
22. Samad F, Yamamoto K, Loskutoff DJ:Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97, 37-46.
23. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S:Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996;93, 106-110.
24. Andreotti F, Davies GJ, Hackett DR, Khan MI, de Bart AC, Aber VR, Maseri A, Kluft C:Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635-637.
25. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO:Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988;59:495-499.
26. Angelton P, Chandler WL, Schmer G:Diurnal variation of tissue-type plasminogen activator and its rapid inhibition. Circulation 1989;79:101-106.
27. Dawson S, Hamsten A, Wiman B, Henney A. Humphries S:Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis Thromb 1991;11:183-190.
28. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM:The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745.
29. Loskutoff DJ, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H:Structure of the human plasminogen activator inhibitor 1 gene:nonrandom distribution of introns. Biochemistry 1987;26:3763-3768.
30. Strandberg L, Lawrence D,. Ny T:The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988;176:609-616.
31. van Hinsbergh VW, Kooistra T. van den Berg EA, Princen HM, Fiers W, Emeis JJ:Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988;72:1467-1473.
32. Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R. Grzeschik KH, Alitalo K, Blasi F, Danø K:Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A 1987;84:8548-8552.
33. Falk G, Almqvist Å, Nordenhem A, Svensson H, Wiman B:Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995;9:170-174.
34. Colucci M, Paramo JA, Collen D:Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J din Invest 1985;75:818-824.
35. Emeis JJ, Kooistra T:Interleukin-1 and lipopolysaccharide induce a fast-acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Experimental Med 1986;163:1260-1266.
36. Eriksson B, Eriksson E, Gyzander E, Teger-Nilsson AC, Thorsen S, Risberg B:Thrombosis after hip replacement, relationship to the fibrinolytic system. Acta Orthop Scand 1989;60:159-163.
37. Wallen P, Bergsdorf N, Rånby M. Purification and characterization of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982;719:318-328.
38. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982;704:461-469.
39. Biessen EA, van Teijlingen M, Vietsch H, Barrett-Bergshoeff MM, Bijsterbosch MK, Rijken DC, van Berkel TJ, Kuiper J. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997;95:46-52.
40. Wiman B, Hamsten A:Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991;34:179-192.
41. Schulman S, Wiman B, for the Duration of Anticoagulation (DURAC) Trial Study Group:The significance of hypofibrinolysis for the risk of recurrence of venous tromboembolism. Thromb Haemostas, in press.
42. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR:Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990;346:74-76.
43. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De-Vos R, van-den-Oord JJ Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.
44. Mellbring G, Dahlgren S, Wiman B:Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand 1985;151:109-114.
45. Paramo JA, Alfaro MJ, Rocha E:Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor - Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemostas 1985;54:713-716.
46. Hamsten A, Wiman B, de Faire U, Blombäck M:Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
47. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year followup. Circulation 1993;88:2030-2034.
48. Reutervall C, Hallqvist J, Ahlbom A, deFaire U, Diderichsen F, Hogstedt C, Pershagen G, Theorell T, Wiman B, Wolk A, and the SHEEP study group. Same risk of myocardial infarctionin men and women? Analysis of some major risk factors in the SHEEP study. J Int Med. In press.
49. Eriksson P, Kallin B, van't Hooft FM. Båvenholm P, Hamsten A:Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855.
50. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F:The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-841.